Skip to content
2000
Volume 4, Issue 4
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

The COVID-19 pandemic has resulted in a socially isolating way of life, and dementia patients are among those who are most affected. Lockdown procedures and the inability to monitor illnesses have led to a rapid decline in cognitive function in these individuals, with neuropsychiatric symptoms, such as agitation, delirium, and impaired motor performance being prevalent. However, the use of antipsychotics in treating these symptoms can increase the risk of death during COVID-19. Effective pain therapy can be used as an alternative to reduce or avoid the use of antipsychotics, given the consistent relationship between agitation and pain in dementia patients. The importance of properly assessing and managing pain in dementia patients is highlighted. Additionally, the article discusses how COVID-19 can affect brain health through inflammation, blood clotting, and blood vessel damage, leading to potential long-term effects on cognitive function. Healthcare professionals must be aware of the increased risk of neuropsychiatric symptoms in dementia patients during the pandemic and prioritize pain management as a viable alternative to antipsychotics. Proper care and attention are necessary to prevent cognitive decline and potential long-term effects on brain health in these vulnerable individuals.

Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975253863230920070917
2023-12-01
2025-10-30
Loading full text...

Full text loading...

/content/journals/covid/10.2174/0126667975253863230920070917
Loading

  • Article Type:
    Review Article
Keyword(s): alzheimer's; COVID-19; dementia; haemorrhage; neuropsychiatric symptoms; SARS-CoV-2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test